2024
The persistent benefits of decreasing default pill counts for postoperative narcotic prescriptions
Coppersmith N, Sznol J, Esposito A, Flom E, Chiu A, Yoo P. The persistent benefits of decreasing default pill counts for postoperative narcotic prescriptions. PLOS ONE 2024, 19: e0304100. PMID: 38833500, PMCID: PMC11149874, DOI: 10.1371/journal.pone.0304100.Peer-Reviewed Original ResearchConceptsOxycodone 5-mg tabletsPill countSurgical proceduresOpioid naive patientsOpioid prescribing habitsPostoperative narcotic prescriptionsQuantity of opioidsPercentage of patientsDay of surgeryClinicians' prescribing practicesElectronic medical record systemOpiate requirementsMorphine equivalentsChi-square testPostoperative opioidsOpioid prescriptionsNarcotic prescriptionsPrescription quantitiesOpioidAffiliated HospitalPrescribing habitsPatientsPrescribing practicesPersistent benefitsAcademic healthcare system
2023
Routine post-operative labs and healthcare system burden in acute appendicitis
Sznol J, Becher R, Maung A, Bhattacharya B, Davis K, Schuster K. Routine post-operative labs and healthcare system burden in acute appendicitis. The American Journal Of Surgery 2023, 226: 571-577. PMID: 37291012, DOI: 10.1016/j.amjsurg.2023.06.005.Peer-Reviewed Original ResearchConceptsHealthcare system burdenSystem burdenHealth care costsAppendicitis managementIncreased LOSUncomplicated AAAcute appendicitisRetrospective cohortClinical courseClinical variablesPatient populationMinimal comorbiditiesMultivariable modelingHealthcare costsCare costsPatientsLaboratory utilizationNational Health Expenditure AccountsLab utilizationLaboratory testingBurdenLaboratory testsAppendicitisComorbiditiesCohortManagement and Outcome of High-Grade Hepatic and Splenic Injuries
Presser E, Sznol J, Schuster K. Management and Outcome of High-Grade Hepatic and Splenic Injuries. Current Surgery Reports 2023, 11: 55-63. DOI: 10.1007/s40137-023-00344-1.Peer-Reviewed Original ResearchSplenic injuryOperative interventionUnstable patientsTrauma grade IVHigh-grade injuriesModality of choiceTransient respondersActive bleedingGrade injuriesSerial examsStable patientsSignificant morbidityPermissive hypotensionEndovascular interventionPrehospital interventionsRadiological studiesTrauma bayBlood productsGrade IVPatientsSecondary surveyInjuryExact indicationsClass IIIActive signs
2014
Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.
Kluger H, Halabi S, Solomon N, Jilaveanu L, Zito C, Sznol J, Nixon A, Rini B, Small E, George D. Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206. Journal Of Clinical Oncology 2014, 32: 4532-4532. DOI: 10.1200/jco.2014.32.15_suppl.4532.Peer-Reviewed Original Research